Page last updated: 2024-11-01

ofloxacin and Hemolytic-Uremic Syndrome

ofloxacin has been researched along with Hemolytic-Uremic Syndrome in 2 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Hemolytic-Uremic Syndrome: A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by hemolytic anemia (ANEMIA, HEMOLYTIC); THROMBOCYTOPENIA; and ACUTE RENAL FAILURE.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ohnishi, K1
Nakamura-Uchiyama, F1
Miedouge, M1
Hacini, J1
Grimont, F1
Watine, J1

Other Studies

2 other studies available for ofloxacin and Hemolytic-Uremic Syndrome

ArticleYear
Does levofloxacin induce hemolytic uremic syndrome in patients infected with verotoxin-producing Escherichia coli O157 infections?
    Japanese journal of infectious diseases, 2012, Volume: 65, Issue:5

    Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Colitis; Escherichia coli Infections; Escherichi

2012
Shiga toxin-producing Escherichia coli urinary tract infection associated with hemolytic-uremic syndrome in an adult and possible adverse effect of ofloxacin therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 30, Issue:2

    Topics: Adult; Aged; Anti-Infective Agents, Urinary; Escherichia coli Infections; Escherichia coli O157; Fem

2000